Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maria Sole Chimenti

Showing results (141-150 of 197) with videos related to

Pageof 20
Sort By:
Clinical Rheumatology|June 8, 2017
Elderly psoriatic arthritis patients on TNF-α blockers: results of an Italian multicenter study on minimal disease activity and drug discontinuation rateLuisa Costa, Ennio Lubrano, Roberta Ramonda, et al.
Seminars in Arthritis and Rheumatism|December 3, 2014
Tumour necrosis factor alpha inhibitor therapy and rehabilitation for the treatment of ankylosing spondylitis: a systematic reviewEnnio Lubrano, Antonio Spadaro, Giorgio Amato, et al.
Clinical and Experimental Rheumatology|May 30, 2019
Demographic and clinical differences between ankylosing spondylitis and non-radiographic axial spondyloarthritis: results from a multicentre retrospective study in the Lazio region of ItalyMaria Sole Chimenti, Paola Conigliaro, Luca Navarini, et al.
Journal of Clinical Medicine|June 26, 2025
Italian Multicenter Real-World Study on the Twelve-Month Effectiveness, Safety, and Retention Rate of Guselkumab in Psoriatic Arthritis PatientsFabiola Atzeni, Cinzia Rotondo, Cesare Siragusano, et al.
Journal of Clinical Medicine|April 28, 2023
Rheumatoid Arthritis from Easy to Complex Disease: From the "2022 GISEA International Symposium"Simone Perniola, Maria Sole Chimenti, Francesca Romana Spinelli, et al.
Clinical and Experimental Rheumatology|July 25, 2024
Effectiveness of ixekizumab over 24 months in different clinical scenarios in psoriatic arthritis: results from the Gruppo Italiano Studio Early Arthritis multicentric prospective registryMaria Sole Chimenti, Mauro Fatica, Marco Fornaro, et al.
Arthritis Research & Therapy|October 11, 2023
Upadacitinib effectiveness and factors associated with minimal disease activity achievement in patients with psoriatic arthritis: preliminary data of a real-life multicenter studyMichele Maria Luchetti Gentiloni, Valentino Paci, Antonio Carletto, et al.
Therapeutic Advances in Musculoskeletal Disease|May 5, 2022
Effectiveness and safety of secukinumab in axial spondyloarthritis: a 24-month prospective, multicenter real-life studyRoberta Ramonda, Mariagrazia Lorenzin, Maria Sole Chimenti, et al.
RMD Open|February 17, 2021
Effectiveness and safety of secukinumab in 608 patients with psoriatic arthritis in real life: a 24-month prospective, multicentre studyRoberta Ramonda, Mariagrazia Lorenzin, Antonio Carriero, et al.
Annals of the Rheumatic Diseases|December 13, 2025
ChatGPT vs rheumatologists: cross-sectional study on accuracy and patient perception of AI-generated information for psoriatic arthritisGiulio Forte, Daniele Mauro, Maura Raimondi, et al.
Pageof 20

Showing results (141-150 of 197) with videos related to

Sort By:
Pageof 20
Clinical Rheumatology|June 8, 2017
Elderly psoriatic arthritis patients on TNF-α blockers: results of an Italian multicenter study on minimal disease activity and drug discontinuation rateLuisa Costa, Ennio Lubrano, Roberta Ramonda, et al.
Seminars in Arthritis and Rheumatism|December 3, 2014
Tumour necrosis factor alpha inhibitor therapy and rehabilitation for the treatment of ankylosing spondylitis: a systematic reviewEnnio Lubrano, Antonio Spadaro, Giorgio Amato, et al.
Clinical and Experimental Rheumatology|May 30, 2019
Demographic and clinical differences between ankylosing spondylitis and non-radiographic axial spondyloarthritis: results from a multicentre retrospective study in the Lazio region of ItalyMaria Sole Chimenti, Paola Conigliaro, Luca Navarini, et al.
Journal of Clinical Medicine|June 26, 2025
Italian Multicenter Real-World Study on the Twelve-Month Effectiveness, Safety, and Retention Rate of Guselkumab in Psoriatic Arthritis PatientsFabiola Atzeni, Cinzia Rotondo, Cesare Siragusano, et al.
Journal of Clinical Medicine|April 28, 2023
Rheumatoid Arthritis from Easy to Complex Disease: From the "2022 GISEA International Symposium"Simone Perniola, Maria Sole Chimenti, Francesca Romana Spinelli, et al.
Clinical and Experimental Rheumatology|July 25, 2024
Effectiveness of ixekizumab over 24 months in different clinical scenarios in psoriatic arthritis: results from the Gruppo Italiano Studio Early Arthritis multicentric prospective registryMaria Sole Chimenti, Mauro Fatica, Marco Fornaro, et al.
Arthritis Research & Therapy|October 11, 2023
Upadacitinib effectiveness and factors associated with minimal disease activity achievement in patients with psoriatic arthritis: preliminary data of a real-life multicenter studyMichele Maria Luchetti Gentiloni, Valentino Paci, Antonio Carletto, et al.
Therapeutic Advances in Musculoskeletal Disease|May 5, 2022
Effectiveness and safety of secukinumab in axial spondyloarthritis: a 24-month prospective, multicenter real-life studyRoberta Ramonda, Mariagrazia Lorenzin, Maria Sole Chimenti, et al.
RMD Open|February 17, 2021
Effectiveness and safety of secukinumab in 608 patients with psoriatic arthritis in real life: a 24-month prospective, multicentre studyRoberta Ramonda, Mariagrazia Lorenzin, Antonio Carriero, et al.
Annals of the Rheumatic Diseases|December 13, 2025
ChatGPT vs rheumatologists: cross-sectional study on accuracy and patient perception of AI-generated information for psoriatic arthritisGiulio Forte, Daniele Mauro, Maura Raimondi, et al.
Pageof 20